Labels
Breast Cancers
(143)
Genitourinary Cancers
(71)
Lung Cancers
(70)
Gastrointestinal Cancers
(66)
Gynecological Cancers
(55)
Head and Neck Cancers
(49)
Cutaneous Cancers
(21)
Central Nervous System Cancers
(11)
Friday 7 September 2012
Adding bavituximab to second-lind chemotherapy doubles response rate
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment